Abstract

T cell development requires the coordinated rearrangement of T cell receptor (TCR) gene segments and the expression of either αβ or γδ TCR. However, whether and how de novo synthesis of nutrients contributes to thymocyte commitment to either lineage remains unclear. Here, we find that T cell-specific deficiency in glutamine:fructose-6-phosphate aminotransferase 1 (GFAT1), the rate-limiting enzyme of the de novo hexosamine biosynthesis pathway (dn-HBP), attenuates hexosamine levels, blunts N-glycosylation of TCRβ chains, reduces surface expression of key developmental receptors, thus impairing αβ-T cell ontogeny. GFAT1 deficiency triggers defects in N-glycans, increases the unfolded protein response, and elevates  γδ-T cell numbers despite reducing γδ-TCR diversity. Enhancing TCR expression or PI3K/Akt signaling does not reverse developmental defects. Instead, dietary supplementation with the salvage metabolite, glucosamine, and an α-ketoglutarate analogue partially restores αβ-T cell development in GFAT1T-/- mice, while fully rescuing it in ex vivo fetal thymic organ cultures. Thus, dn-HBP fulfils, while salvage nutrients partially satisfy, the elevated demand for hexosamines during early T cell development.

Although T cell commitment to specific lineages coincides with the rearrangement of T cell receptor loci, it remains unclear whether metabolism also influences this process. Here, authors show that de novo hexosamine biosynthesis promotes  αβ T cell lineage commitment and γδ-TCR diversity and can be modulated by dietary supplementation.

Details

Title
Dietary glucosamine overcomes the defects in αβ-T cell ontogeny caused by the loss of de novo hexosamine biosynthesis
Author
Werlen, Guy 1   VIAFID ORCID Logo  ; Li, Mei-Ling 1 ; Tottone, Luca 2   VIAFID ORCID Logo  ; da Silva-Diz, Victoria 3 ; Su, Xiaoyang 4 ; Herranz, Daniel 3   VIAFID ORCID Logo  ; Jacinto, Estela 1   VIAFID ORCID Logo 

 The State Univ. of New Jersey, Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers, Piscataway, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796) 
 The State Univ. of New Jersey, Dept. of Pharmacology and Pediatrics, Robert Wood Johnson Medical School, and Rutgers Cancer Institute of New Jersey, Rutgers, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796); University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, USA (GRID:grid.26790.3a) (ISNI:0000 0004 1936 8606) 
 The State Univ. of New Jersey, Dept. of Pharmacology and Pediatrics, Robert Wood Johnson Medical School, and Rutgers Cancer Institute of New Jersey, Rutgers, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796) 
 The State Univ. of New Jersey, Dept. of Medicine, Div. of Endocrinology, Child Health Inst. of New Jersey, Rutgers, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2743830927
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.